Clinical research study of SPARC1612 in breast cancer
Not Applicable
Completed
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: null- Metastatic breast cancer
- Registration Number
- CTRI/2016/06/007043
- Lead Sponsor
- Sun Pharma Advanced Research Company Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 28
Inclusion Criteria
The subject has given written, informed consent (or
legally acceptable representative /impartial
witness when applicable) and is available for the
duration of study
- Histologically or cytologically confirmed diagnosis of breast cancer
- Locally recurrent or MBC for which taxane-based therapy is an appropriate
treatment option
- Male or female aged >= 18 years
Exclusion Criteria
- Presence of clinically symptomatic active CNS metastases
- Pre-existing clinically significant peripheral neuropathy
- Inability to undergo venipuncture and/or tolerate venous access
- Known hypersensitivity to either of the study drugs or their excipients
Study & Design
- Study Type
- BA/BE
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method